Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCCP Cyclacel Pharmaceuticals, Inc. daily Stock Chart
CYCCP [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own- Shs Outstand12.50M Perf Week-9.68%
Market Cap69.99M Forward P/E- EPS next Y- Insider Trans- Shs Float10.16M Perf Month0.00%
Income- PEG- EPS next Q- Inst Own1.09% Short Float0.00% Perf Quarter-3.78%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.12 Perf Half Y-15.66%
Book/sh1.38 P/B4.05 EPS next Y- ROA- Target Price- Perf Year20.43%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.85 - 7.00 Perf YTD-10.40%
Dividend0.60 P/FCF- EPS past 5Y- ROI- 52W High-20.00% Beta-
Dividend %10.71% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low15.46% ATR0.39
Employees12 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)48.41 Volatility0.12% 3.43%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close5.60
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume0.98K Price5.60
Recom- SMA203.14% SMA50-4.66% SMA200-11.38% Volume84 Change0.00%
Jan-07-19 07:00AM  Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 GlobeNewswire -9.77%
Dec-27-18 07:00AM  Cyclacel Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco GlobeNewswire
Nov-12-18 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire +11.13%
Nov-06-18 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results GlobeNewswire
Oct-23-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-04-18 07:00AM  Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies GlobeNewswire
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.